Diagnostic testing plays a major role in modern medicine, supporting up to 70% of clinical decisions1. A massive global market, combined with an ongoing desire to detect diseases as early as possible, makes novel diagnostic technology a highly fertile area for investment.
Point-of-care testing (POCT) is of considerable interest to clinicians and payors alike, as it has the potential to improve outcomes by optimising prescribing decisions, reducing referrals and enhancing efficiency of care2,3.
"The driving concept in support of POCT is to bring testing closer to the patient and results conveniently and quickly to the provider, to expedite diagnosis and subsequent treatment."
Kim Futrell, MT (ASCP), June 2015 4
Glyconics is a company at the forefront of diagnostic innovation, using infrared spectroscopy to analyse samples for markers of disease across a wide range of conditions.
So join us on a journey to find out more about our technology and the opportunities it presents.
To date, FTIR Spectroscopy could only be undertaken in a laboratory by highly trained staff. With Glyconics technology, however, that's changing.
Glyconics is developing a compact, cost-effective way of using FTIR Spectroscopy for point-of-care testing. Our hand-held device identifies spectra waves from samples resulting in highly accurate diagnostic data in minutes.
The quality of our project is such that the European Commission has awarded Glyconics a coveted Seal of Excellence certificate, following evaluation by an independent panel of international experts.5
Glyconics is developing point-of-care testing in a wide range of areas including oncology, urology and particularly chronic obstructive pulmonary disease (COPD) as the latter is a widespread condition in need of diagnostic innovation.
Success in this area promises major financial rewards, as the COPD market is huge. A staggering 200 million people in the EU, UK, USA, China, India have COPD6, with 36.6 million newly diagnosed cases each year. Around 1 in 10 of these patients are at risk of exacerbations and need daily monitoring, adding up to 1.3 billion tests per annum. Glyconics is perfectly placed to meet the need for diagnostic innovation in this area.
Dr Berwyn Clarke – Executive Chairman
Founded Lab21 Limited in 2005, a new diagnostics company in the UK. Went on to establish a network of diagnostics industry interests in 2013. He is currently Chairman of NALIA Systems Ltd and PBD Biotech Ltd, as well as being non-executive director at Protein Logic.
Dr Kam Pooni – Chief Executive Officer
An experienced, proven and award winning Senior Leader, Kam has over 20 years expertise in building and energising geographically dispersed teams to deliver first-rate, value added results. Kam has over 10 years’ experience in re-engineering marketing, sales and commercial strategy and its subsequent execution, to deliver the P&L commitment. Previously, Kam was a Senior Director at Astellas Pharmaceuticals Europe in a number of diverse senior roles. He has worked internationally based in Europe , the USA, Latin America, Asia, the Middle East and Africa.
Mike Lewis – Non-Executive Director
Mike has 30 years global Health industry experience. He is currently: Executive Chair iPlato leader in mHealth; Chairman of Cambridge Cognition plc a neuroscience Diagnostics developer; Chairman of Biomonde, a Wales based Surgery company; and Chair of Haemo2, a Biotech developing artificial haemoglobin. He has been an industrial advisor for private equity organisations and has worked with Apax Partners, Advent International and Electra Capital. Mike has also worked with the ICENI group and various Universities including Imperial College, London and University of Essex. Previously, he was CEO of Ranier Technology, EMEA President of medical device company Gambro and also was Head of Global Marketing, Strategy and Product Development. Gambro was subsequently sold for $3,9Bn to private equity company EQT/Investor. He has held senior roles in operations, general management, strategy, marketing and sales at Align Technology (based in Amsterdam), Boston Scientific (based in Paris) and Becton Dickinson, Merck and Sandoz (based in the UK).
Savvas Neophytou – Non-Executive Director – Deepbridge Capital
A partner at Deepbridge Capital and Head of Life Sciences. Before joining Deepbridge in January 2016, Savvas enjoyed a 15 year career in the City, working as an investment banker and ECM at JP Morgan, Bear Stearns, Shore Capital, Cantor Fitzgerald and Panmure Gordon.
Jeremy Williams – Non-Executive Director
In addition to his role at Glyconics, Jeremy is founder of Stratus Communications Ltd, helping businesses to improve their performance and manage rapid growth. Prior to this, Jeremy was CEO and owner of ScopeMedical Ltd, a medical communications provider with clients from the global pharmaceutical industry. Creating and implementing global healthcare communication programmes, ScopeMedical Ltd was acquired by Huntsworth Plc in an £11m acquisition in 2010.
Sam Smart – Finance Director
Sam has over 15 years' experience in finance and management, supporting several young healthcare companies. She has corporate finance deal and fund-raising experience from her time at PricewaterhouseCoopers LLP.
Niall Gallen – Chief Technology Officer
A recognised expert in FTIR subject matter and highly experienced in the transfer of design to production. Also has extensive experience in leading manufacturing and engineering services for medtech and industrial products.
We would love to tell you more about Glyconics and our investment opportunities. Please call or email to arrange a visit, to meet our team and see our groundbreaking technology for yourself.
St John’s Innovation Centre, Cowley Road, Cambridge, CB4 0WS
TERMS AND CONDITIONS
© 2017 - ALL RIGHTS RESERVED GLYCONICS
1. The Lewin Group, Inc. The value of diagnostics innovation, adoption and diffusion into health care, 2005. Available at: https://dx.advamed.org/sites/dx.advamed.org/files/resource/Lewin%20Value%20of%20 Diagnostics %20Report.pdf [accessed 23 June 2015]
2. Price CP, St John A, Kricka LJ. eds Point-of-care testing. Washington: AACC Press, 2010.
3. Geersing GJ, Janssen KJ, Oudega R, et al. Excluding venous thromboembolism using point of care D-dimer tests in outpatients: a diagnostic meta-analysis. BMJ 2009;339:b2990.
4. Futrell, K. Point-of-Care Testing: A Future Outlook, 2015. Available at: www.himss.org/file/1308651/download?token= 2jGKS9bM [accessed 23 June 2015]
5. Seal of Excellence awarded by the European Commission in June 2016 for project proposal 734194, COPD-DX: Development of a Miniaturised Infra-red (IR) Spectrometer for Improved Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) and Early Identification of Exacerbation.
6. Burr J. COPD Factsheet – June 2015. Available at: www.howz.com/copd-factsheet-june-2015/ [accessed 28 June 2017]